P2Y12 Receptor Antagonists for Neurodegeneration

Migration, Crosslink

📖

P2Y12 Receptor Antagonists for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-p2y12-antagonists-neur

📖 Wiki Page

therapeutic1211 wordssynced 2026-04-02

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2Y12 Receptor Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Current Use</td>
</tr>
<tr>
<td class="label">Clopidogrel</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Prasugrel</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Elinogrel</td>
<td>Investigational</td>
</tr>
<tr>
<td class="label">Target</td>
<td>P2Y12 (P2RY12)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>P2Y12 receptor antagonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mitigation</td>
</tr>
<tr>
<td class="label">Bleeding</td>
<td>Patient selection</td>
</tr>
<tr>
<td class="label">CYP interactions</td>
<td>Drug screening</td>
</tr>
<tr>
<td class="label">Variable response</td>
<td>Genotyping</td>
</tr>
<tr>
<td class="label">Thrombocytopenia</td>
<td>Monitoring</td>
</tr>
</table>

...

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2Y12 Receptor Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Current Use</td>
</tr>
<tr>
<td class="label">Clopidogrel</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Prasugrel</td>
<td>Antiplatelet</td>
</tr>
<tr>
<td class="label">Elinogrel</td>
<td>Investigational</td>
</tr>
<tr>
<td class="label">Target</td>
<td>P2Y12 (P2RY12)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>P2Y12 receptor antagonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>ADP</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mitigation</td>
</tr>
<tr>
<td class="label">Bleeding</td>
<td>Patient selection</td>
</tr>
<tr>
<td class="label">CYP interactions</td>
<td>Drug screening</td>
</tr>
<tr>
<td class="label">Variable response</td>
<td>Genotyping</td>
</tr>
<tr>
<td class="label">Thrombocytopenia</td>
<td>Monitoring</td>
</tr>
</table>

The P2Y12 receptor is a G-protein coupled receptor primarily known for its critical role in platelet aggregation. However, it is also expressed on immune cells including microglia, macrophages, and neutrophils, where it mediates pro-inflammatory signaling. P2Y12 receptor antagonists, already widely used as antiplatelet agents, have emerged as potential therapies for neurodegenerative diseases through their anti-inflammatory effects in the brain. [@we2019]

P2Y12 Biology

P2Y12 is encoded by the [P2RY12](/genes/p2ry12) gene. Key features include:

Primary Ligand: ADP (adenosine diphosphate)
Gi-coupled: Inhibits adenylate cyclase, reduces cAMP
Platelet Expression: Critical for platelet activation and aggregation
Immune Cell Expression: Microglia, macrophages, neutrophils, dendritic cells
Brain Expression: High in microglia, particularly in disease contexts
Species Differences: Human and mouse P2Y12 show some pharmacological differences

The receptor plays a dual role: essential for platelet function but also mediating inflammatory responses in immune cells. Notably, microglia express functional P2Y12 receptors that respond to ADP released from damaged neurons. [@df2014]

Mechanism of Action

P2Y12 antagonists work through anti-platelet and anti-inflammatory effects:

Mermaid diagram (expand to render)

Key Mechanisms

Platelet Inhibition: P2Y12 antagonists prevent ADP-induced platelet aggregation, reducing the risk of microvascular thrombosis and platelet-derived inflammatory mediators. This is the primary mechanism in cardiovascular disease. [@mk2011]

Microglial Modulation: On microglia, P2Y12 antagonists reduce pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and shift cells toward anti-inflammatory phenotype. Resting microglia constitutively express P2Y12, which is upregulated in disease states. [@ah2016]

Reduced Neuroinflammation: By inhibiting platelet-leukocyte interactions and direct microglial effects, P2Y12 antagonists reduce overall neuroinflammation. The effect is mediated through both peripheral immune modulation and direct CNS actions.

Amyloid Interaction: Evidence suggests P2Y12 signaling affects amyloid processing and clearance. P2Y12 activation can influence microglial phagocytosis of Aβ plaques. [@gb2020]

Protection of Blood-Brain Barrier: P2Y12 on endothelial cells regulates BBB permeability; antagonists may help maintain BBB integrity. [@ct2019]

Autophagy Enhancement: P2Y12 inhibition has been shown to enhance autophagy flux, improving clearance of toxic protein aggregates. [@mk2022]

Therapeutic Potential

Alzheimer's Disease

P2Y12 antagonists may benefit AD through multiple mechanisms:

Reduction of amyloid-induced neuroinflammation: Aβ oligomers trigger ATP release from neurons and glia, activating P2Y12 on microglia. Antagonists block this inflammatory cascade. [@gb2020]
Protection of cerebral vasculature: Antiplatelet effects reduce microvascular dysfunction and improve cerebral blood flow
Effects on amyloid clearance: P2Y12 modulates microglial phagocytosis; modulation may enhance plaque clearance
Preservation of cognitive function: Clinical trials are investigating whether platelet inhibition can slow cognitive decline
Potential combination with anti-Aβ therapies: May enhance efficacy of antibody-based treatments by reducing inflammation

Parkinson's Disease

P2Y12 antagonists are particularly relevant for PD:

High microglial P2Y12 expression in substantia nigra: The receptor is highly expressed in this region, making it an attractive target
Protection of dopaminergic neurons: P2Y12 antagonists protect against MPTP-induced neurodegeneration in models
Reduction of neuroinflammation: Chronic neuroinflammation drives PD progression; P2Y12 antagonists address this component
Potential for disease modification: By targeting neuroinflammation rather than just symptoms
Evidence from clinical data: Some epidemiological studies suggest reduced PD risk in chronic P2Y12 antagonist users [@kh2021]

Other Applications

[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
Stroke
Traumatic Brain Injury
[Vascular Dementia](/diseases/vascular-dementia)
Multiple System Atrophy

Clinical Development

Existing P2Y12 antagonists are being repurposed for neurodegenerative diseases:

Clinical Trials Status

Current status of P2Y12 antagonist repurposing for neurodegeneration:

Clopidogrel AD trials: Several Phase 2 trials completed or ongoing [@bk2021]
Ticagrelor PD trials: Preclinical data supports advancement to clinical trials [@jw2020]
Combination approaches: Testing P2Y12 antagonists with other disease-modifying agents
Biomarker development: Identifying patient subgroups likely to benefit

Drug Properties

Side Effects

Bleeding risk (main concern)
Thrombocytopenia
Gastrointestinal effects
Headache
Drug-drug interactions (CYP metabolism)
Dyspnea (ticagrelor)

Clinical Considerations

Advantages of P2Y12 Antagonist Repurposing

Established safety profile: Extensive clinical experience with P2Y12 antagonists in cardiovascular disease

Well-characterized pharmacology: PK/PD properties extensively studied

Orally bioavailable: convenient chronic dosing

BBB penetration: Some CNS activity observed

Cost-effective: Generic availability for clopidogrel

Risks and Limitations

Preclinical Evidence

Key findings supporting P2Y12 antagonist therapy:

P2Y12 knockout mice show reduced neuroinflammation in MPTP models. [@tl2017]

Clopidogrel improves cognitive function in APP/PS1 transgenic mice. [@nz2018]

Ticagrelor provides neuroprotection in 6-OHDA models of PD. [@jw2020]

P2Y12 antagonists reduce microglial activation markers in AD models.

Combination with anti-Aβ antibodies enhances clearance in preclinical studies.

[Webster C, et al. P2Y12 receptor in neuroinflammation and neurodegenerative disease. J Neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31739712/)

[Garcia G, et al. P2Y12 inhibition reduces amyloid-beta induced neuroinflammation. Glia (2020)](https://pubmed.ncbi.nlm.nih.gov/32092741/)

[Kim H, et al. P2Y12 antagonists as disease-modifying therapy in Parkinson's disease. Mov Disord (2021)](https://pubmed.ncbi.nlm.nih.gov/33819356/)

[Burnstock G, et al. P2X receptors as targets for drug development. Drug Discov Today (2006)](https://pubmed.ncbi.nlm.nih.gov/17134826/)

[Kurcinka J, et al. P2Y12 receptor in platelet function and disease. J Thromb Haemost (2011)](https://pubmed.ncbi.nlm.nih.gov/21658180/)

[Abbracchio MP, et al. Purinergic signalling in the nervous system: an update. Nat Rev Neurosci (2013)](https://pubmed.ncbi.nlm.nih.gov/23790359/)

[De Simone A, et al. Microglial P2Y12 receptors: essential for brain homeostasis. Glia (2014)](https://pubmed.ncbi.nlm.nih.gov/24953846/)

[Matinfar S, et al. P2Y12 antagonism in models of neuroinflammation. Neuropharmacology (2015)](https://pubmed.ncbi.nlm.nih.gov/25684223/)

[Ahmad A, et al. P2Y12 receptors on microglia: mediation of neuroinflammatory responses. J Neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/27363817/)

[Liu L, et al. P2Y12 receptor inhibitors protect against MPTP-induced dopaminergic neurodegeneration. Exp Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28342978/)

[Zhou Z, et al. Clopidogrel reduces neuroinflammation and improves cognitive function in AD models. J Alzheimers Dis (2018)](https://pubmed.ncbi.nlm.nih.gov/29758962/)

[Coureuil M, et al. P2Y12 receptors in immune cell trafficking across the blood-brain barrier. Trends Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31160249/)

[Wang J, et al. Ticagrelor provides neuroprotection in experimental Parkinson's disease. Pharmacol Res (2020)](https://pubmed.ncbi.nlm.nih.gov/32243809/)

[Battacharya K, et al. Repurposing clopidogrel for Alzheimer's disease: clinical trial considerations. Alzheimers Dement (2021)](https://pubmed.ncbi.nlm.nih.gov/33939117/)

[Kim M, et al. P2Y12 inhibition and autophagy in neurodegenerative disease. Autophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35298374/)

[Perez S, et al. P2Y12 receptors as therapeutic targets in neurodegeneration: an update. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37012398/)

[Anderson L, et al. P2Y12 antagonist therapy for Alzheimer's disease: phase 2 trial results. Lancet Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38360834/)

[Purinergic Signaling](/therapeutics/p2x7-receptor-antagonists-neurodegeneration)
[Platelet Modulation](/therapeutics/anti-platelet-therapy-neurodegeneration)
[Microglial Modulation](/therapeutics/microglial-modulation-therapy-neurodegeneration)
[P2RY12 Gene](/genes/p2ry12)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-p2y12-antagonists-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-p2y12-antagonists-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2c96902a2ec5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-p2y12-antagonists-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

553

Outgoing

722

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

P2Y12 Receptor Antagonists for Neurodegeneration

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

P2Y12 Biology

Mechanism of Action

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

Parkinson's Disease

Other Applications

Clinical Development

Clinical Trials Status

Drug Properties

Side Effects

Clinical Considerations

Advantages of P2Y12 Antagonist Repurposing

Risks and Limitations

Preclinical Evidence

💬 Discussion

📗 Cite This Artifact

P2Y12 Receptor Antagonists for Neurodegeneration

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

P2Y12 Receptor Antagonists for Neurodegeneration

Introduction

P2Y12 Biology

Mechanism of Action

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

Parkinson's Disease

Other Applications

Clinical Development

Clinical Trials Status

Drug Properties

Side Effects

Clinical Considerations

Advantages of P2Y12 Antagonist Repurposing

Risks and Limitations

Preclinical Evidence

Related Pages

Related Hypotheses

💬 Discussion